JP2024522820A5 - - Google Patents
Info
- Publication number
- JP2024522820A5 JP2024522820A5 JP2023578189A JP2023578189A JP2024522820A5 JP 2024522820 A5 JP2024522820 A5 JP 2024522820A5 JP 2023578189 A JP2023578189 A JP 2023578189A JP 2023578189 A JP2023578189 A JP 2023578189A JP 2024522820 A5 JP2024522820 A5 JP 2024522820A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- tqs
- composition according
- administered
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163211636P | 2021-06-17 | 2021-06-17 | |
| US63/211,636 | 2021-06-17 | ||
| US202263300551P | 2022-01-18 | 2022-01-18 | |
| US63/300,551 | 2022-01-18 | ||
| PCT/US2022/034012 WO2022266455A1 (en) | 2021-06-17 | 2022-06-17 | Therapeutically effective oral administration of a 2 arylbenzimidazole |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024522820A JP2024522820A (ja) | 2024-06-21 |
| JP2024522820A5 true JP2024522820A5 (enExample) | 2025-06-25 |
Family
ID=84527631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023578189A Pending JP2024522820A (ja) | 2021-06-17 | 2022-06-17 | ２－アリールベンゾイミダゾールの治療上有効な経口投与 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20240307356A1 (enExample) |
| EP (1) | EP4355326A4 (enExample) |
| JP (1) | JP2024522820A (enExample) |
| WO (1) | WO2022266455A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202416960A (zh) * | 2022-06-17 | 2024-05-01 | 美商特朗奎斯治療股份有限公司 | 2-芳基苯并咪唑化合物之調配物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3000985C (en) * | 2014-10-14 | 2023-01-31 | The Board Of Trustees Of The Leland Stanford Junior University | Method for treating neurodegenerative diseases |
| AU2016371598B2 (en) * | 2015-12-15 | 2021-05-13 | The Board Of Trustees Of The Leland Stanford Junior University | Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation |
| US20240316008A1 (en) * | 2020-06-22 | 2024-09-26 | Tranquis Therapeutics, Inc. | Treatment of systemic immune activation syndromes |
-
2022
- 2022-06-17 WO PCT/US2022/034012 patent/WO2022266455A1/en not_active Ceased
- 2022-06-17 JP JP2023578189A patent/JP2024522820A/ja active Pending
- 2022-06-17 EP EP22825909.9A patent/EP4355326A4/en active Pending
- 2022-06-17 US US18/571,177 patent/US20240307356A1/en not_active Abandoned
-
2025
- 2025-01-13 US US19/019,406 patent/US20250281462A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2221563C2 (ru) | Фармацевтическая композиция для лечения болезни паркинсона и синдромов паркинсона, способ ее получения, способ лечения болезни паркинсона и синдромов паркинсона | |
| AU2009227629B2 (en) | Dosing regimen for a selective S1P1 receptor agonist | |
| CN117137912A (zh) | 选择性s1p1受体激动剂的给药方案 | |
| JP2022544711A5 (enExample) | ||
| JP2026035701A5 (enExample) | ||
| JP2023552700A5 (enExample) | ||
| JP2024522820A5 (enExample) | ||
| JPH0761923A (ja) | アルツハイマー病治療剤 | |
| JP2022514537A5 (enExample) | ||
| JP2022500485A5 (enExample) | ||
| JP2023548429A5 (enExample) | ||
| EP1154766B1 (de) | Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln, zur behandlung von erkrankungen bei mensch und tier, welche durch die hemmung der aktivierung von nf-kappa b therapeutisch beeinflusst werden können | |
| JP2025157438A5 (enExample) | ||
| JP2023518640A5 (enExample) | ||
| DE60125062T2 (de) | Quetiapin zur Behandlung der Dyskinesie in nicht-psychotischen Patienten | |
| JP2021530568A5 (enExample) | ||
| JP2024543347A5 (enExample) | ||
| JP2024545496A5 (enExample) | ||
| CN1290166A (zh) | 运动障碍的治疗 | |
| JP2022550458A5 (enExample) | ||
| JPS5936615A (ja) | 発がん予防剤 | |
| JP6188784B2 (ja) | 炎症性および免疫性疾患の治療のための組成物 | |
| JP2024541770A5 (enExample) | ||
| US20170112804A1 (en) | Lipoic acid and derivatives thereof for the treatment of cystinuria | |
| WO2004096230A1 (ja) | 関節リウマチ治療剤 |